Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDA Filings Drop In 2004: Latest Sign Of Concern For R&D Productivity

Executive Summary

The pharmaceutical industry is continuing to face declining output from its R&D investment

You may also be interested in...



NDA filings hold steady

The 116 NDAs received by CDER in calendar year 2005 continues a trend of modest growth since a user fee-era low of 98 NDAs received in 2001. The 2005 figure is comparable to the 115 NDA receipts in 2004, which was a modest bump from 109 in 2003 due to the transfer of therapeutic biologics to CDER in October 2003. The numbers have been revised from last year's figures, likely due to reclassification of the submissions; the previous NDA receipts were recorded as 103 for 2004 and 110 for 2003 (1"The Pink Sheet" April 4, 2005, p. 14). FDA has predicted continued modest growth in applications in fiscal 2006 and 2007, but the agency cautions that it does not expect high NDA receipts to translate into more approval (2"The Pink Sheet" Feb. 13, 2006, p. 6) ...

NDA filings hold steady

The 116 NDAs received by CDER in calendar year 2005 continues a trend of modest growth since a user fee-era low of 98 NDAs received in 2001. The 2005 figure is comparable to the 115 NDA receipts in 2004, which was a modest bump from 109 in 2003 due to the transfer of therapeutic biologics to CDER in October 2003. The numbers have been revised from last year's figures, likely due to reclassification of the submissions; the previous NDA receipts were recorded as 103 for 2004 and 110 for 2003 (1"The Pink Sheet" April 4, 2005, p. 14). FDA has predicted continued modest growth in applications in fiscal 2006 and 2007, but the agency cautions that it does not expect high NDA receipts to translate into more approval (2"The Pink Sheet" Feb. 13, 2006, p. 6) ...

COX-2 Backlash? Fewer First-Cycle Approvals Would Signal Tougher FDA

A first-cycle drug approval rate significantly lower than 40% could provide the first sign of an effect of COX-2 inhibitor safety issues on FDA reviews, a report from the contract research organization Parexel states

Related Content

Topics

UsernamePublicRestriction

Register

OM016808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel